| Target Price | ¥2,167.50 |
| Price | ¥1,527.50 |
| Potential |
41.90%
register free of charge
|
| Number of Estimates | 10 |
|
10 Analysts have issued a price target Santen Pharmaceutical 2026 .
The average Santen Pharmaceutical target price is ¥2,167.50.
This is
41.90%
register free of charge
¥2,730.00
78.72%
register free of charge
¥1,717.00
12.41%
register free of charge
|
|
| A rating was issued by 13 analysts: 9 Analysts recommend Santen Pharmaceutical to buy, 4 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Santen Pharmaceutical stock has an average upside potential 2026 of
41.90%
register free of charge
|
| Mar '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion ¥ | 300.00 | 296.94 |
| 0.65% | 1.02% | |
| EBITDA Margin | 19.11% | 21.02% |
| 7.19% | 10.02% | |
| Net Margin | 12.08% | 11.87% |
| 36.98% | 1.76% |
11 Analysts have issued a sales forecast Santen Pharmaceutical 2026 . The average Santen Pharmaceutical sales estimate is
This results in the following potential growth metrics:
11 Analysts have issued an Santen Pharmaceutical EBITDA forecast 2026. The average Santen Pharmaceutical EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
11 Santen Pharmaceutical Analysts have issued a net profit forecast 2026. The average Santen Pharmaceutical net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Mar '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share ¥ | 103.65 | 104.72 |
| 43.28% | 1.03% | |
| P/E | 14.64 | |
| EV/Sales | 1.66 |
11 Analysts have issued a Santen Pharmaceutical forecast for earnings per share. The average Santen Pharmaceutical EPS is
This results in the following potential growth metrics and future valuations:
Santen Pharmaceutical...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


